ASH 2013: Highlights in Chronic Myelogenous Leukemia

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: December 19, 2013
Expiration Date: December 19, 2014

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this educational activity, clinical experts discuss key findings relative to new and emerging treatments for chronic myelogenous leukemia (CML) from the 2013 ASH Meeting. Each module will focus on the latest data, on what the data means in the clinical setting, and how clinicians may effectively incorporate this information to improve patient care, and ultimately, patient outcomes.

Target Audience

This activity is designed for oncologists, nurses, nurse practitioners, physician assistants, and pharmacists who provide care to patients with CML.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize updates in CML clinical guidelines regarding use of emerging and approved therapies and their placement in the treatment continuum
  • Describe how recent clinical trial findings may translate into practice for individual patient needs and treatment goals
  • Identify current trials and agents in clinical investigation

Agenda

ASH 2013: Highlights in Chronic Myelogenous Leukemia – Neil P. Shah, MD, PhD, Moderator

Prognostic Value of Response Rates from Baseline by Three Months and the Four-Year Update from the ENESTnd and DASISION Trials: Safety and Efficacy of Second-Generation TKIs versus Imatinib for Newly Diagnosed CP-CML – Jorge Eduardo Cortes, MD

Highlights from Targeting Tyrosine Kinase Receptors – Michael Deininger, MD, PhD

TKI Discontinuation Studies and Insights into Predicting Which Patients May Relapse After Discontinuation: Euro-SKI and DADI Trials – Satu Mustjoki, MD, PhD

Follow-up of the Phase II PACE Trial and Clinical Impact of Dose Modification on Response to Ponatinib in Patients with Chronic Phase Chronic Myeloid Leukemia – Javier Pinilla-Ibarz, MD, PhD

Highlights of Alternative Approaches to Eradicating the Malignant Clone in Chronic Myeloid Leukemia: Tyrosine Kinase Inhibitor Combinations and Beyond – Richard A. Van Etten, MD, PhD

Instructions for Participation and Credit

This activity is eligible for credit through December 19, 2014. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Neil P. Shah, MD, PhD
Associate Professor
Division of Hematology and Oncology
UCSF School of Medicine
San Francisco, California

Dr. Neil Shah received his PhD in microbiology and molecular genetics at the University of California, Los Angeles (UCLA), and his medical degree from the UCLA School of Medicine. He continued his postdoctoral training at UCLA with an internship and residency in internal medicine, followed by a fellowship in hematology and oncology. Dr. Shah is the Edward S. Ageno Distinguished Professor of Hematology/Oncology at UCSF, and leader of the Hematopoietic Malignancies Program at the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Shah is a diplomate in internal medicine, medical oncology, as well as hematology of the American Board of Internal Medicine. He has authored or co-authored numerous publications largely focused on chronic myeloid leukemia (CML), a disease of the hematopoietic pluripotent stem cell. Dr. Shah’s research interests focus on understanding molecular mechanisms of disease response and resistance to targeted therapeutics in human myeloid malignancies.

Jorge Eduardo Cortes, MD
Professor of Medicine and Deputy Chair
Chief of the CML Section
Department of Leukemia
The University of Texas, MD Anderson Cancer Center
Houston, Texas

Dr. Jorge Cortes received his medical degree from Faculty of Medicine of the National Autonomous University of Mexico along with postgraduate training at The National Institute of Medical Sciences and Nutrition Salvador Zubirán. He also completed a hematology fellowship at The University of Texas Health Science Center at Houston, and a hematology/oncology fellowship at The University of Texas, MD Anderson Cancer Center. Dr. Cortes is professor of medicine and deputy chair, and is also the chief of the CML Section in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center.

Dr. Cortes has authored hundreds of peer-reviewed articles, abstracts, book chapters, and medical publications. He is editor-in-chief of Clinical Leukemia, and Current Malignant Hematology Reports, and is on the editorial board of Clinical Cancer Research, Leukemia, and Journal of Clinical Oncology. In addition, Dr. Cortes serves on the Board of Directors for The Leukemia & Lymphoma Society. His clinical interests focus on new drug development and the management of patients with acute and chronic leukemia.

Michael Deininger, MD, PhD
Professor and Chief of Hematology and Hematologic Malignancies
Department of Internal Medicine
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Dr. Michael Deininger received his medical degree from the University of Würzburg Medical School, Germany, and his PhD from Imperial College, London. He trained in internal medicine and hematology/oncology, and completed a fellowship in stem cell transplantation at the University of Leipzig Medical Center. Dr. Deininger is professor and chief of hematology and hematologic malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah.

Dr. Deininger is a member of the Chronic Leukemia Working Party, American Society of Hematology, and American Society of Clinical Oncology. He has written almost 200 articles in peer-reviewed journals including Blood, Journal of Clinical Investigation and The New England Journal of Medicine, has co-authored many book chapters, and contributed to leading textbooks. He is a regular speaker at major international scientific meetings.

Dr. Deininger’s scientific focus is leukemia, specifically myeloproliferative neoplasms including chronic myeloid leukemia (CML). Current work in his lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets, and developing more specific signal transduction inhibitors.

Satu Mustjoki, MD, PhD
Adjunct Professor
Experimental Hematology
University of Helsinki
Helsinki, Finland

Dr. Satu Mustjoki received her medical degree at the University of Helsinki, Finland, and continued as a PhD student in the cancer biology group at Haartman Institute, Helsinki. She completed a specialty degree in clinical chemistry in the Laboratory of Hematology, Helsinki University Central Hospital, Finland. Dr. Mustjoki is an adjunct professor (docent) of experimental hematology at the University of Helsinki and currently holds a position as academy research fellow at the Helsinki University Central Hospital.

The main themes in Dr. Mustjoki’s research have been the immunological aspects of leukemia therapy, leukemia stem cell targeting, and discovery of novel therapy targets. These research projects have led to several publications in high-impact journals such as Blood, Leukemia, and The New England Journal of Medicine, and the discoveries made in these projects have impacted the design of several academic clinical drug studies.

Javier Pinilla-Ibarz, MD, PhD
Associate Professor
Department of Oncologic Sciences
College of Medicine
University of South Florida
Tampa, Florida.

Dr. Javier Pinilla-Ibarz received both his medical degree and PhD from the University of Zaragoza, School of Medicine, Spain. He completed a residency in medicine and a fellowship in hematology at La Paz University Hospital in Madrid, Spain, and also completed a residency in internal medicine at Cornell Medical Center, as well as a fellowship in hematology/oncology at the Memorial Sloan-Kettering Cancer Center. Dr. Pinilla-Ibarz is an associate professor in the Department of Oncologic Sciences, College of Medicine, University of South Florida.

Dr. Pinilla-Ibarz is an associate member of the Malignant Hematology and Immunology Program at the H. Lee Moffitt Cancer Center in Tampa, and is leading the chronic leukemia program whose principal interest is patients with myeloid and lymphoid chronic leukemia. He has participated in multiple clinical trials involving tyrosine kinase inhibitors, some of them now approved. Dr. Pinilla-Ibarz is also the director of immunotherapy for malignant hematology and has been involved in developing new immunotherapeutic approaches in chronic myelogenous leukemia (CML.) He is currently leading several clinical trials of peptide and cellular vaccines in different hematological disorders. Other research focuses are on the role of the bone marrow microenvironment in mediating resistance to TKIs and the interaction of TKIs with the immune system.

Dr. Pinilla-Ibarz frequently presents his findings at annual meetings of the American Hematology Association, American Society of Clinical Oncology, and other national/international meetings. His work has been published in journals including Blood, Nature Immunology, Seminars of Hematology, and Leukemia. He has also authored multiple book chapters.

Richard A. Van Etten, MD, PhD
Professor of Medicine
Director, Chao Family Comprehensive Cancer Center
University of California, Irvine
Orange, California

Dr. Richard Van Etten received his medical degree and his PhD in biophysics from Stanford University. He completed a residency in internal medicine and fellowship in hematology at Brigham & Women’s Hospital, Boston. Dr. Van Etten is professor of medicine and director of the Chao Family Comprehensive Cancer Center, University of California, Irvine.

A diplomate of the National Board of Medical Examiners, American Board of Internal Medicine, and hematology subspecialty board certification, Dr. Van Etten also holds memberships in the American Association for the Advancement of Science, American College of Physicians, American Society of Hematology, and the Eastern Cooperative Oncology Group. He is associate editor of Blood, is on the editorial board of Journal of Clinical Oncology, and is an ad hoc reviewer for numerous peer-review journals.       

Dr. Van Etten’s major research interests include the function and regulation of c-ABL protein; mechanisms of leukemogenesis by BCR-ABL; identification of novel therapeutic strategies for Philadelphia-positive leukemia; and assessment of targeted therapeutic agents for hematologic malignancies.

Accreditation

CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-380-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-380-341

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Neil Shah has received consultant fees as well as grant support related to research activities from ARIAD Pharmaceuticals, Inc., and Bristol-Myers Squibb.

Dr. Jorge Cortes has received honoraria as a consultant from ARIAD Pharmaceuticals, Bristol-Myers Squibb, Pfizer Inc., Inc., and Teva Pharmaceuticals, as well as grant support related to research activities from ARIAD, Bristol-Myers Squibb, Novartis AG, Pfizer and Teva.

Dr. Javier Pinilla-Ibarz has received honoraria related to formal advisory activities and as a consultant from ARIAD Pharmaceuticals, Bristol-Myers Squibb, Novartis AG, and Pfizer Inc., and speakers’ bureau activities from Pfizer Inc.

Dr. Michael Deininger has disclosed no relevant financial relationships.

Dr. Satu Mustjoki has received honoraria related to formal advisory activities and as a consultant, as well as grant support related to research activities from Bristol-Myers Squibb and Novartis AG.

Dr. Richard Van Etten has received honoraria as a consultant from Bristol-Myers Squibb and Teva Pharmaceuticals. He has received grant support related to research activities from Teva.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene Tombler, PhD, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. Shah, Cortes, Deininger, and Mustjoki have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Pinilla-Ibarz and Dr. Van Etten have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Shah, Cortes, Deininger, and Mustjoki have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Dr. Pinilla-Ibarz and Dr. Van Etten have indicated that the do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@ManagingCML.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Teva Pharmaceuticals and Novartis.

©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.